6-氨基-3,5-二溴吡啶甲酸甲酯 | 443956-21-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氨基-3,5-二溴吡啶甲酸甲酯
• 英文名称: methyl 6-amino-3,5-dibromopicolinate
• 英文别名: methyl 6-amino-3,5-dibromopyridine-2-carboxylate
• CAS: 443956-21-6
• 化学式: C₇H₆Br₂N₂O₂
• 分子量: 309.945
• InChiKey: RLNKFHZYSZFLTL-UHFFFAOYSA-N

物化性质

• 沸点：
  366.0±37.0 °C(Predicted)
• 密度：
  1.997

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  储存条件：2-8°C，避光，保存于惰性气体中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 6-amino-3,5-dibromopicolinate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 6-amino-3,5-dibromopicolinate
CAS number: 443956-21-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6Br2N2O2
Molecular weight: 309.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氨基-3,5-二溴吡啶甲酸甲酯 在 3-巯基丙酸乙酯 、 sodium hydride 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 16.0h， 以2.4 g的产率得到methyl 6-amino-3-bromo-5-mercaptopicolinate hydrochloride
  参考文献：
  名称：

  [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
  [FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE

  摘要：

  公式I的化合物，包括其药用可接受的盐，以及用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法被提出：I

  公开号：

  WO2018203235A1
• 作为产物：
  描述：

  6-氨基-3-溴吡啶甲酸甲酯 在 溴 作用下， 以 氯仿 为溶剂， 反应 18.0h， 生成 6-氨基-3,5-二溴吡啶甲酸甲酯
  参考文献：
  名称：

  [EN] NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS
  [FR] HETEROCYCLES BICYCLIQUES CONTENANT DE L'AZOTE ET UTILISES COMME PRODUITS ANTIBACTERIENS

  摘要：

  环己烷和环己烯衍生物及其在哺乳动物，特别是人类细菌感染治疗方法中有用的药用可接受衍生物。

  公开号：

  WO2003087098A1

文献信息

• [EN] ANTI PARASITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME<br/>[FR] DIHYDROAZOLES ANTIPARASITAIRES ET COMPOSITIONS LES INCLUANT
  申请人：MERIAL LTD

  公开号：WO2011075591A1

  公开（公告）日：2011-06-23

  The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

  本发明涉及式(I)的新型二氢咪唑及其盐：其中R1、A1、A2、G、X和Y如描述中所定义，以及它们的组合物、制备方法以及它们用于预防或治疗动物寄生虫感染或寄生虫侵袭以及作为杀虫剂的用途。
• [EN] IMIDAZOPYRIDINES SYK INHIBITORS<br/>[FR] INHIBITEURS DE SYK À BASE D'IMIDAZOPYRIDINES
  申请人：GILEAD SCIENCES INC

  公开号：WO2011112995A1

  公开（公告）日：2011-09-15

  Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

  本文提供了某些咪唑吡啶(I)及其药物组合物。提供了治疗对Syk活性抑制敏感的患者患有某些疾病和疾病的方法，包括向这些患者施用至少一种有效减轻疾病或疾病症状的化学实体。还提供了一种确定样本中Syk激酶存在或不存在的方法。
• ANTIPARISITIC DIHYDROAZOLE COMPOUNDS AND COMPOSITIONS COMPRISING SAME
  申请人：Le Hir de Fallois Loic Patrick

  公开号：US20110152312A1

  公开（公告）日：2011-06-23

  The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R 1 , A 1 , A 2 , G, X and Y are as defined in the description, compositions thereof, processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

  本发明涉及式(I)的新型二氢咪唑及其盐： 其中R1、A1、A2、G、X和Y如描述中所定义，以及它们的组合物、制备方法以及它们在预防或治疗动物寄生虫感染或寄生虫侵袭以及作为杀虫剂中的用途。
• IMIDAZOPYRIDINES SYK INHIBITORS
  申请人：Blomgren Peter A.

  公开号：US20140148430A1

  公开（公告）日：2014-05-29

  Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

  本文提供了某些咪唑吡啶(I)及其药物组合物。提供了治疗对Syk活性抑制敏感的患者患有某些疾病和疾病的方法，包括向这些患者施用至少一种有效减轻疾病或疾病症状的化学实体。还提供了一种确定样本中Syk激酶存在或不存在的方法。
• [EN] CAPSID INHIBITORS FOR THE TREATMENT OF HIV<br/>[FR] INHIBITEURS DE CAPSIDE POUR LE TRAITEMENT DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2021262990A1

  公开（公告）日：2021-12-30

  The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

  本公开涉及一些化合物，包括所述化合物的药物组合物，以及制备和使用所述化合物和药物组合物的方法。本文披露的化合物和组合物可用于治疗或预防Retroviridae病毒感染，包括由HIV病毒引起的感染。